193 related articles for article (PubMed ID: 22922441)
1. SAHA, an HDAC inhibitor, synergizes with tacrolimus to prevent murine cardiac allograft rejection.
Zhang X; Han S; Kang Y; Guo M; Hong S; Liu F; Fu S; Wang L; Wang QX
Cell Mol Immunol; 2012 Sep; 9(5):390-8. PubMed ID: 22922441
[TBL] [Abstract][Full Text] [Related]
2. SAHA, an HDAC inhibitor, attenuates antibody-mediated allograft rejection.
Zhang X; Guo M; Kang Y; Liu F; Zheng X; Han S; Fu S; Hong S; Ding G; Wang L; Wang QX
Transplantation; 2013 Sep; 96(6):529-37. PubMed ID: 23912176
[TBL] [Abstract][Full Text] [Related]
3. Synergistic effects of Isatis tinctoria L. and tacrolimus in the prevention of acute heart rejection in mice.
Wang Y; Qin Q; Chen J; Kuang X; Xia J; Xie B; Wang F; Liang H; Qi Z
Transpl Immunol; 2009 Dec; 22(1-2):5-11. PubMed ID: 19766187
[TBL] [Abstract][Full Text] [Related]
4. Effects of histone deacetylase inhibitor SAHA on effector and FOXP3+regulatory T cells in rhesus macaques.
Johnson J; Pahuja A; Graham M; Hering B; Hancock WW; Bansal-Pakala P
Transplant Proc; 2008 Mar; 40(2):459-61. PubMed ID: 18374101
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of Histone Deacetylase 6 Reveals a Potent Immunosuppressant Effect in Models of Transplantation.
Ellis JD; Neil DA; Inston NG; Jenkinson E; Drayson MT; Hampson P; Shuttleworth SJ; Ready AR; Cobbold M
Transplantation; 2016 Aug; 100(8):1667-74. PubMed ID: 27222932
[TBL] [Abstract][Full Text] [Related]
6. IL-2 therapy restores regulatory T-cell dysfunction induced by calcineurin inhibitors.
Whitehouse G; Gray E; Mastoridis S; Merritt E; Kodela E; Yang JHM; Danger R; Mairal M; Christakoudi S; Lozano JJ; Macdougall IC; Tree TIM; Sanchez-Fueyo A; Martinez-Llordella M
Proc Natl Acad Sci U S A; 2017 Jul; 114(27):7083-7088. PubMed ID: 28584086
[TBL] [Abstract][Full Text] [Related]
7. Improving allogeneic islet transplantation by suppressing Th17 and enhancing Treg with histone deacetylase inhibitors.
Sugimoto K; Itoh T; Takita M; Shimoda M; Chujo D; SoRelle JA; Naziruddin B; Levy MF; Shimada M; Matsumoto S
Transpl Int; 2014 Apr; 27(4):408-15. PubMed ID: 24410777
[TBL] [Abstract][Full Text] [Related]
8. Effect of a new immunosuppressant histon deacetylase (HDAC) inhibitor FR276457 in a rat cardiac transplant model.
Kinugasa F; Yamada T; Noto T; Matsuoka H; Mori H; Sudo Y; Mutoh S
Biol Pharm Bull; 2008 Sep; 31(9):1723-6. PubMed ID: 18758066
[TBL] [Abstract][Full Text] [Related]
9. Modulation of renal disease in MRL/lpr mice by suberoylanilide hydroxamic acid.
Reilly CM; Mishra N; Miller JM; Joshi D; Ruiz P; Richon VM; Marks PA; Gilkeson GS
J Immunol; 2004 Sep; 173(6):4171-8. PubMed ID: 15356168
[TBL] [Abstract][Full Text] [Related]
10. Histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits anti-inflammatory activities through induction of mitochondrial damage and apoptosis in activated lymphocytes.
Shi ZJ; Ouyang DY; Zhu JS; Xu LH; He XH
Int Immunopharmacol; 2012 Apr; 12(4):580-7. PubMed ID: 22369900
[TBL] [Abstract][Full Text] [Related]
11. Tacrolimus and cyclosporine differ in their capacity to overcome ongoing allograft rejection as a result of their differential abilities to inhibit interleukin-10 production.
Jiang H; Wynn C; Pan F; Ebbs A; Erickson LM; Kobayashi M
Transplantation; 2002 Jun; 73(11):1808-17. PubMed ID: 12085006
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
13. Controlled release of an HDAC inhibitor for reduction of inflammation in dry eye disease.
Ratay ML; Balmert SC; Bassin EJ; Little SR
Acta Biomater; 2018 Apr; 71():261-270. PubMed ID: 29526828
[TBL] [Abstract][Full Text] [Related]
14. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.
Shi YK; Li ZH; Han XQ; Yi JH; Wang ZH; Hou JL; Feng CR; Fang QH; Wang HH; Zhang PF; Wang FS; Shen J; Wang P
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1131-40. PubMed ID: 20838997
[TBL] [Abstract][Full Text] [Related]
15. Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy.
Chen MY; Liao WS; Lu Z; Bornmann WG; Hennessey V; Washington MN; Rosner GL; Yu Y; Ahmed AA; Bast RC
Cancer; 2011 Oct; 117(19):4424-38. PubMed ID: 21491416
[TBL] [Abstract][Full Text] [Related]
16. Reduction of Foxp3-expressing regulatory T cell infiltrates during the progression of renal allograft rejection in a mouse model.
Wang S; Jiang J; Guan Q; Lan Z; Wang H; Nguan CY; Jevnikar AM; Du C
Transpl Immunol; 2008 May; 19(2):93-102. PubMed ID: 18503884
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase inhibitors modulate interleukin 6-dependent CD4+ T cell polarization in vitro and in vivo.
Glauben R; Sonnenberg E; Wetzel M; Mascagni P; Siegmund B
J Biol Chem; 2014 Feb; 289(9):6142-51. PubMed ID: 24421314
[TBL] [Abstract][Full Text] [Related]
18. Suberoylanilide hydroxamic acid induces limited changes in the transcriptome of primary CD4(+) T cells.
Beliakova-Bethell N; Zhang JX; Singhania A; Lee V; Terry VH; Richman DD; Spina CA; Woelk CH
AIDS; 2013 Jan; 27(1):29-37. PubMed ID: 23221426
[TBL] [Abstract][Full Text] [Related]
19. The Histone-Deacetylase-Inhibitor Suberoylanilide Hydroxamic Acid Promotes Dental Pulp Repair Mechanisms Through Modulation of Matrix Metalloproteinase-13 Activity.
Duncan HF; Smith AJ; Fleming GJ; Partridge NC; Shimizu E; Moran GP; Cooper PR
J Cell Physiol; 2016 Apr; 231(4):798-816. PubMed ID: 26264761
[TBL] [Abstract][Full Text] [Related]
20. Protective effect of suberoylanilide hydroxamic acid against LPS-induced septic shock in rodents.
Li Y; Liu B; Zhao H; Sailhamer EA; Fukudome EY; Zhang X; Kheirbek T; Finkelstein RA; Velmahos GC; deMoya M; Hales CA; Alam HB
Shock; 2009 Nov; 32(5):517-23. PubMed ID: 19295477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
